PGPEP1 Antibody

What is PGPEP1 and why is it important in research?

PGPEP1 (Pyroglutamyl-Peptidase I) is an omega peptidase that removes pyroglutamyl residues from the amino termini of peptides and proteins . This cytosolic cysteine peptidase is expressed in most cell types and requires a thiol-reducing agent for activity . It plays a potentially significant role in the inactivation of biologically active peptides that possess an amino terminal pyroglutamyl group, including neurotensin, luteinizing hormone releasing hormone, and thyrotropin-releasing hormone .

Recent research has identified circular RNA derived from the PGPEP1 gene (circPGPEP1) as being associated with colorectal cancer malignancy, suggesting broader implications for PGPEP1 in disease mechanisms . The enzyme belongs to the peptidase C15 family and has a molecular weight of approximately 23 kDa .

What applications are most suitable for PGPEP1 antibodies?

PGPEP1 antibodies are validated for multiple experimental applications with varying recommended dilutions:

When selecting an application, consider that PGPEP1 antibodies have been successfully used to detect the protein in various sample types including human brain tissue, prostate cancer cell lines (LNCaP), choriocarcinoma cell lines (JAR), testicular embryonic carcinoma cell lines (NTera-2), and mouse neuroblastoma cell lines (Neuro-2A) .

What is the expected molecular weight of PGPEP1 in Western blot experiments?

When performing Western blot analysis with PGPEP1 antibodies, researchers should expect to observe a band at approximately 20-23 kDa . In validation studies using human brain (cortex) tissue and various cell lines, a specific band was detected for PGPEP1 at approximately 23 kDa . This is consistent with the calculated molecular weight of PGPEP1, which is 23 kDa . Note that slight variations in the observed molecular weight may occur depending on post-translational modifications or the specific tissue/cell type being examined.

How should I optimize Western blot conditions for PGPEP1 detection?

For optimal detection of PGPEP1 by Western blot, consider the following protocol parameters:

• Sample preparation: Use reducing conditions as demonstrated in validation studies .

• Membrane type: PVDF membranes have been successfully used for PGPEP1 detection .

• Antibody concentration: Use primary antibody at 1 μg/mL (for R&D Systems Sheep Anti-Human PGPEP-1) or at dilutions of 1:500-1:1000 (for Proteintech's antibody) .

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (e.g., Anti-Sheep IgG for R&D Systems antibody) .

• Buffer system: Immunoblot Buffer Group 1 has been effectively used in validation studies .

Always include positive control samples such as human brain tissue, which has demonstrated consistent PGPEP1 expression in multiple studies .

What cell lines or tissue samples are recommended for PGPEP1 antibody validation?

Based on the search results, the following cell lines and tissue samples have been successfully used for PGPEP1 antibody validation:

Cell lines:

• LNCaP (human prostate cancer cell line)

• JAR (human choriocarcinoma cell line)

• NTera-2 (human testicular embryonic carcinoma cell line)

• Neuro-2A (mouse neuroblastoma cell line)

• HepG2 cells (for immunofluorescence)

Tissue samples:

• Human brain cortex tissue

• Human placenta (for immunohistochemical analysis)

When validating a new PGPEP1 antibody, including at least one of these established positive control samples is recommended to ensure reliable performance comparison with previously published results.

What are the recommended storage conditions for PGPEP1 antibodies?

Proper storage of PGPEP1 antibodies is crucial for maintaining their activity and specificity. Based on manufacturer recommendations:

For reconstituted antibodies, R&D Systems recommends:

• 1 month at 2-8°C under sterile conditions

• 6 months at -20 to -70°C under sterile conditions

Following these storage guidelines will help maintain antibody performance and extend shelf life.

How can I detect and study circPGPEP1 in colorectal cancer research?

Recent research has identified circular RNA derived from the PGPEP1 gene (circPGPEP1) as being significantly upregulated in colorectal cancer (CRC) tissues . To study circPGPEP1:

• PCR detection: Use the following primers for circPGPEP1 detection:

  • Forward: 5"-GCATGTGTACGAGATTCCGG-3"

  • Reverse: 5"-TGTGTGTGTTTGCCAAGACC-3"

• Structural validation: Confirm the circular structure of circPGPEP1 using:

  • Actinomycin D treatment (circRNAs have longer half-lives than linear mRNAs)

  • RNase R digestion (circRNAs are resistant to RNase R)

  • Northern blot analysis

• Expression analysis: Compare expression levels between:

  • CRC tissues and adjacent normal tissues

  • CRC cell lines and normal colon mucosal cells

• Clinical correlation: Analyze the relationship between circPGPEP1 expression and:

  • Lymph node metastasis

  • Survival prognosis (using Kaplan-Meier method)

This approach has revealed that circPGPEP1 is associated with lymph node metastasis and poor survival prognosis in CRC patients, suggesting its potential as a biomarker or therapeutic target .

What methodologies can be used to study PGPEP1's role in peptide regulation?

To investigate PGPEP1's role in regulating peptides with N-terminal pyroglutamyl residues:

• Enzymatic activity assays: Design assays to measure PGPEP1 activity using fluorogenic or chromogenic substrates containing pyroglutamyl residues.

• Substrate identification: Use mass spectrometry to identify peptides processed by PGPEP1, focusing on neurotensin, luteinizing hormone releasing hormone, and thyrotropin-releasing hormone as known targets .

• Protein interaction studies: Employ co-immunoprecipitation with PGPEP1 antibodies to identify binding partners that may regulate its activity or localization.

• Thiol-dependence characterization: Investigate the requirement for thiol-reducing agents for PGPEP1 activity, as noted in the literature .

• Functional studies: Use PGPEP1 knockdown or overexpression in relevant cell models, followed by quantification of target peptide levels.

Understanding PGPEP1's regulatory role may provide insights into neuropeptide signaling pathways and potential therapeutic interventions for related disorders.

How does PGPEP1 expression vary across different tissues and species?

Based on the available information, PGPEP1 is expressed in multiple tissues and shows high conservation across species:

Tissue expression:

• Human brain cortex tissue shows detectable PGPEP1 expression

• Human placenta demonstrates strong cytoplasmic positivity in immunohistochemical analysis

• Expression has been validated in multiple cancer cell lines including LNCaP, JAR, NTera-2, and Neuro-2A

Cross-species conservation:

• Human and mouse PGPEP1 share 95% amino acid sequence identity

• Antibody immunogens show high conservation:

  • 97% sequence identity between human and mouse

  • 96% sequence identity between human and rat

  • Some antibodies react with human, mouse, and rat samples

This high degree of conservation suggests that PGPEP1 plays a fundamental biological role conserved throughout evolution, making it possible to use the same antibodies across multiple species in comparative studies.

Why might I see multiple bands when using PGPEP1 antibodies in Western blot?

Multiple bands in Western blot when using PGPEP1 antibodies may result from several factors:

• Post-translational modifications: While the canonical molecular weight of PGPEP1 is 23 kDa, modifications like phosphorylation or glycosylation could result in higher molecular weight bands.

• Antibody cross-reactivity: Some antibodies may cross-react with structurally similar proteins, especially other members of the peptidase C15 family.

• Protein degradation: Incomplete protease inhibition during sample preparation may generate lower molecular weight fragments.

• Alternative splice variants: Though not specifically mentioned in the search results, alternative splicing could produce protein isoforms of different sizes.

To address this issue:

• Include positive control samples with known PGPEP1 expression (e.g., human brain tissue)

• Test multiple antibodies that target different epitopes of PGPEP1

• Optimize sample preparation protocols to minimize degradation

• Consider performing peptide competition assays to confirm specificity

How can I optimize immunofluorescence experiments with PGPEP1 antibodies?

For successful immunofluorescence detection of PGPEP1:

• Cell selection: Use cell lines with validated PGPEP1 expression, such as HepG2 cells which have shown positive IF/ICC detection .

• Antibody dilution: Start with the recommended dilution range of 1:10-1:100 for IF/ICC applications , then optimize for your specific experimental conditions.

• Fixation method: Test both paraformaldehyde (for structural preservation) and methanol (for better antigen accessibility) fixation methods to determine which works best for your PGPEP1 antibody.

• Blocking conditions: Use 5-10% normal serum (from the species in which the secondary antibody was raised) to minimize background staining.

• Controls:

  • Include a negative control (primary antibody omitted)

  • If possible, include a PGPEP1 knockdown sample as a specificity control

  • Consider co-staining with markers of subcellular compartments to confirm the cytoplasmic localization of PGPEP1

• Signal amplification: For weak signals, consider using tyramide signal amplification or more sensitive detection systems.

These optimizations should help achieve specific staining with minimal background in immunofluorescence experiments.

What approaches can be used to quantify PGPEP1 levels in experimental samples?

Several methodologies can be employed to quantify PGPEP1 levels:

• Western blot densitometry:

  • Run samples alongside a standard curve of recombinant PGPEP1 protein

  • Normalize band intensity to housekeeping proteins like GAPDH

  • Use software such as ImageJ for quantification

• ELISA:

  • Multiple PGPEP1 antibodies are validated for ELISA applications

  • Develop a sandwich ELISA using two antibodies targeting different epitopes

  • Create a standard curve using recombinant human PGPEP1 protein

• qPCR for mRNA quantification:

  • Use validated primers for PGPEP1:

    • Reference housekeeping genes like GAPDH (Forward: 5'- CATCAACGGGAAGCCCATC-3', Reverse: 5"- CTCGTGGTTCACACCCATC-3")

  • Calculate relative expression using the 2^(-ΔΔCt) method

• Mass spectrometry:

  • For absolute quantification, use isotope-labeled peptide standards

  • For relative quantification across samples, use label-free quantification

These approaches offer complementary information about PGPEP1 expression at both protein and mRNA levels, providing a comprehensive understanding of its regulation in experimental systems.

What is the potential significance of PGPEP1 in disease mechanisms?

Recent research has revealed potential roles for PGPEP1 in disease mechanisms:

• Cancer biology: CircPGPEP1, a circular RNA derived from the PGPEP1 gene, has been found to be significantly upregulated in colorectal cancer tissues and is associated with lymph node metastasis and poor survival prognosis . This suggests that PGPEP1-derived transcripts may have important functions in cancer progression.

• Neuropeptide signaling: Given PGPEP1's role in removing pyroglutamyl residues from peptides including neurotensin and thyrotropin-releasing hormone , dysregulation of PGPEP1 could potentially impact signaling pathways involved in neurological and endocrine disorders.

• Protein quality control: As a peptidase involved in protein processing, PGPEP1 may contribute to protein quality control mechanisms, and its dysfunction could theoretically play a role in protein misfolding disorders.

Future research using PGPEP1 antibodies in disease models and patient samples could further elucidate these potential connections and identify novel therapeutic targets.

How can researchers verify the specificity of their PGPEP1 antibody results?

To ensure the specificity and reliability of PGPEP1 antibody results:

• Multiple antibody validation: Use at least two different antibodies targeting distinct epitopes of PGPEP1 to confirm consistent results.

• Genetic manipulation controls:

  • Include PGPEP1 knockdown samples (siRNA, shRNA, or CRISPR-Cas9)

  • Use PGPEP1 overexpression systems as positive controls

• Peptide competition assays: Pre-incubate the antibody with a blocking peptide containing the immunogen sequence to confirm signal specificity.

• Cross-species validation: Given the high conservation between human and mouse PGPEP1 (95% amino acid identity) , consistent results across species can support antibody specificity.

• Immunoprecipitation-mass spectrometry: Perform IP with the PGPEP1 antibody followed by mass spectrometry to confirm pulldown of PGPEP1 and identify any off-target interactions.

These validation approaches collectively provide strong evidence for antibody specificity and increase confidence in experimental results.